Search results
12 lip 2024 · This guidance document provides recommendations to clinicians for treatment of infections caused by extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and difficult-to-treat Pseudomonas aeruginosa (DTR-P. aeruginosa).
- Infection Prevention & Control
IDSA/SHEA: Primer on Healthcare Epidemiology, Infection...
- Guideline Development Process
Because of the large number of clinical practice guidelines...
- Ebola
What is Ebola? Ebola virus disease is a severe illness that...
- Evaluation and Management Services
Dr. Timothy Sullivan, Vice Chair of IDSA’s Coding & Payment...
- Bio-Preparedness Workforce Pilot
On Thursday, June 15, in Washington, D.C., Axios health care...
- Lyme Disease
IDSA engages in advocacy efforts that support better Lyme...
- ID Match
The IDSA ID Match Resolution provides guiding principles for...
- Hepatitis C
Viral hepatitis is a silent epidemic. According to the...
- Infection Prevention & Control
19 kwi 2022 · For this guidance document, ESBL-E will refer to presumed or confirmed ESBL-producing E. coli, K. pneumoniae, K. oxytoca, or P. mirabilis. Treatment recommendations for ESBL-E infections listed below assume that in vitro activity of preferred and alternative antibiotics has been demonstrated.
27 paź 2020 · This guidance document provides recommendations for the treatment of infections caused by extended-spectrum β-lactamase–producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa).
25 sie 2022 · The initial guidance document on infections caused by extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa) was published on 17 September 2020.
5 paź 2024 · Non-septic patients with UTI, cUTI, or pyelonephritis do not need empiric carbapenem coverage according to the most recent IDSA guidelines. In septic or non-urinary tract ESBL-E infection, cover with IV carbapenems as opposed to higher-generation cephalosporins.
18 lip 2023 · Guidance is presented in the form of answers to a series of clinical questions for each pathogen. Although brief descriptions of notable clinical trials, resistance mechanisms, and antimicrobial susceptibility testing (AST) methods are included, the document does not provide a comprehensive review of these topics.
18 kwi 2022 · Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
